Kimia Biosciences Ltd.
BBSE:KIMIABL30.05
INR
+0.08
(+0.27%)
ISIN
INE285U01025
Return %
Stock
S&P 500
1Y
-14.73
14.20
3Y
-22.53
81.12
5Y
-28.88
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sameer Goel
- Full Time Employees
- 205
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 974, Aggarwal Millennium Tower II New Delhi DE India 110034
- IPO Date
- Mar 21, 2016
- Website
- kimiabiosciences.com
- Similar Companies
- Business
- Kimia Biosciences Ltd. manufactures and sells active pharmaceutical ingredients (APIs), key starting materials (KSMs), and intermediates focused on high-potential therapeutic segments including anti-hypertensives, anti-diabetics, anti-coagulants, gastro-intestinal agents, anti-histamines, anti-convulsants, anti-bacterials, anti-fungals, and vitamins; its commercial API portfolio features products such as Acotiamide Hydrochloride, Apixaban, Azelnidipine, Benfotiamine, Benidipine Hydrochloride, Bilastine, Brivaracetam, Citicoline Sodium, Dapagliflozin Propanediol Monohydrate, Delafloxacin Meglumine, Empagliflozin, Fimasartan Potassium Trihydrate, Imeglimin Hydrochloride, Luliconazole, Mirabegron, Oxaceprol, Prucalopride Succinate, Rivaroxaban, Sacubitril Sodium, Sacubitril Valsartan, Teneligliptin Hydrobromide Hydrate, and Ursodeoxycholic Acid, supported by WHO GMP accreditation, DSIR R&D recognition, and certificates including COPP, WC, and OP DMF. The company provides comprehensive CDMO-CRO services encompassing route scouting, process optimization and development, analytical method validation, process safety evaluation, stability studies, and scale-up from preclinical to commercial phases, alongside discovery support for small molecule programs from hit-to-IND. Founded in 1993 and headquartered in Gurugram, Haryana, India, with a corporate office in New Delhi, Kimia Biosciences operates manufacturing facilities in Bhondsi and exports to over 30 countries across Asia, Europe, Africa, Latin America, and the Americas, targeting innovator pharma companies and generic markets worldwide. Recent developments include facility upgrades with modern microbiology labs, water systems, five clean rooms, and in-house micronization in 2018; expansion of nutraceutical exports to the U.S., approvals in South Africa and Taiwan, launches in China, and filings in the EU; filing of multiple patents and DCGI-approved APIs as first- and second-time launches in India; appointment of a Chief Operating Officer in May 2024 and release of financial results with the 32nd Annual Report for FY 2024-25 in November 2024; and investor updates on board meetings, statutory compliance, and trading window closures as of November 2024.